Filtration decisions made during pharmaceutical process development can influence throughput, validation strategy, equipment selection and future GMP manufacturing. A scalable filtration strategy therefore considers not only the filter used in the laboratory, but also how the same process function will be implemented at pilot and production scale.
Development can begin with compact capsule filters, single-use assemblies or other small-scale filtration configurations. As the process matures, manufacturers can continue with a scalable single-use filtration architecture, transition to membrane cartridges in sanitary housings, or use a combination of disposable and reusable technologies. The correct route depends on process scale, filtration area, batch strategy, equipment integration and validation requirements.
Scale-up works best when membrane chemistry, filtration mechanism and integrity-testing strategy remain as consistent as practical while filter area and equipment format are adapted to increasing process volume.
Early development is used to determine whether a membrane and filter configuration are compatible with the process fluid and capable of delivering the required filtration performance.
Small capsule filters are useful because they allow membrane evaluation with limited product volume and relatively simple process integration.
Pilot studies establish how throughput, pressure behaviour, fouling and required filtration area change as batch size increases.
This stage should provide the engineering data required to select the final production format rather than simply reproducing the laboratory setup at a larger physical size.
Production can use single-use capsule-based filtration, reusable cartridge systems in sanitary housings or a hybrid architecture. Selection should follow the validated process rather than a fixed rule that one filter format is always required for production.
Filter format should be selected according to required filtration area, throughput, batch frequency, cleaning strategy and process integration. The membrane technology and validated filtration function are often more important for continuity than the external filter format itself.
Capsule filters combine the filter media and housing in one disposable unit. They are well suited to laboratory development, pilot studies, small-batch processing and compatible single-use production systems.
Because the filter housing is already integrated, no separate reusable cartridge housing is required. Capsule formats can therefore provide a practical route from membrane screening into larger disposable filtration processes.
Explore Capsule Filters →
A single-use filtration system combines filtration with the surrounding disposable fluid path. Capsule filters can be integrated with tubing, bags, bottles, manifolds, connectors and process interfaces as one defined assembly.
This architecture can continue from development into pharmaceutical and biotechnology production when the required filtration area, throughput and manufacturing strategy are suitable for a disposable system.
Explore Single-Use Bioprocess Solutions →
Membrane cartridges provide a scalable filtration format where larger effective filtration area, multiple filter elements or integration into permanent sanitary process equipment is required.
Where comparable membrane technology is available, a process can move from development-scale capsule filtration to cartridge filtration while maintaining relevant membrane characteristics and filtration principles.
Explore Membrane Cartridges →One of the most useful scale-up principles is to avoid unnecessary changes in membrane chemistry or filtration mechanism. When possible, development and production formats should use comparable membrane technology and retention characteristics so that pilot data remains relevant during scale-up.
| Parameter | Why it matters during scale-up |
|---|---|
| Membrane material | PES, PTFE, PVDF, Nylon and other membrane technologies interact differently with aqueous liquids, gases, solvents and sensitive products. Changing membrane chemistry can change process performance and may require additional evaluation. |
| Pore rating & filter grade | Retention requirements should remain defined throughout development and production. Pore size alone does not establish sterilizing-grade validation. |
| Effective filtration area | Required area increases with batch volume and depends on throughput, fouling behaviour and allowable process time. |
| Surface properties | Hydrophilic or hydrophobic behaviour influences wetting, application suitability and integrity-testing methodology. |
| Product compatibility | The membrane, support layers, seals and other product-contact materials must remain suitable for the actual process fluid and operating conditions. |
| Integrity-test strategy | Where integrity testing is required, the method and acceptance criteria should correspond to the exact membrane-filter configuration and validated application. |
Scale-up should be based on measured process behaviour rather than on batch volume alone. Pilot testing helps determine how much effective filtration area is required and whether the selected filter remains practical under representative process conditions.
Determine how much product can be processed through a defined filtration area before performance becomes limiting.
Monitor differential pressure as filtration progresses to understand fouling and establish practical operating limits.
Calculate whether the required production batch can be filtered within the available processing window.
Translate representative pilot data into the filtration area required for the intended batch size and operating margin.
When the production process requires greater filtration area or a permanent reusable installation, membrane cartridges can be integrated into sanitary stainless-steel filter housings.
Housing selection should consider cartridge length and quantity, required filtration area, process connections, drainage, operating pressure, temperature and the facility's cleaning or sterilisation strategy.
Maintaining a comparable membrane technology between the development capsule and the production cartridge can help preserve relevant filtration behaviour while allowing the physical system to increase in scale.
For processes requiring membrane integrity verification, the test strategy should be considered during development rather than added only after the production system has been finalised.
Membrane behaviour, wetting liquid, test pressure, filter format and validated acceptance criteria influence which method is appropriate. Depending on the membrane and application, testing can include Diffusion / Forward Flow, Bubble Point or Water Flow / Water Intrusion-type methods.
Commonly applied to suitable wetted membrane filters by measuring gas diffusion at a defined test pressure.
Evaluates pressure behaviour associated with displacement of wetting liquid from the largest effective membrane pores.
Water-based integrity testing can be appropriate for suitable hydrophobic membrane filters, including selected gas and vent applications.
Pre-use and post-use integrity-testing requirements should be defined according to the application, validated process and applicable quality strategy.
Compact hand-portable testing platform for laboratories, cleanrooms and production locations. Compatible capsules and small-format filters can be tested directly.
View it-02 →
Mobile trolley-based integrity-testing workstation for routine production use across multiple test locations, with optional automatic-wetting configurations.
View ita-02 →Scale-up becomes more complex when the production process introduces unnecessary changes in membrane chemistry, filter construction, wetting behaviour, integrity-test methodology or process conditions.
Changing membrane material during scale-up can alter compatibility, adsorption, flow behaviour and retention characteristics and may require additional process evaluation.
Moving from capsule to cartridge does not necessarily require a change in membrane technology. Where comparable membrane configurations are available, the physical format can change while preserving important filtration characteristics.
Integrity-testing strategy should be aligned with the final validated filter. Introducing a new test method late in development can create additional qualification and documentation work.
The general principles of membrane continuity, filter sizing and integrity-testing strategy must ultimately be applied to the requirements of the specific pharmaceutical product and manufacturing process.
| Question | Scale-up information |
|---|---|
| What is the process fluid? | Define formulation, solvent system, biological content and relevant compatibility considerations. |
| What is the filtration objective? | Clarification, particulate reduction, critical membrane filtration, gas filtration, venting or another defined process function. |
| Which membrane was evaluated? | Record membrane chemistry, filter grade, pore rating and relevant test configuration. |
| What throughput was demonstrated? | Document product volume per effective filtration area together with pressure and process-time behaviour. |
| What will the production architecture be? | Single-use capsule system, reusable cartridge system or hybrid process configuration. |
| How will the filter be integrated? | Define tubing, process connections, bags, housings, skids, filling equipment or other interfaces. |
| Is integrity testing required? | Define applicable test method, wetting procedure, acceptance criteria, timing and reporting requirements. |
| What documentation is required? | Identify relevant validation, material, traceability, qualification and process documentation before final equipment selection. |
Share your process fluid, current development filter, batch volume, demonstrated throughput, operating conditions and expected production scale. Filtra can help evaluate the transition to a scalable single-use or reusable filtration configuration.
Scale-up normally begins by defining suitable membrane chemistry and filtration performance at laboratory scale. Pilot studies then evaluate throughput, fouling, pressure behaviour and required filtration area. The production system can subsequently use a scalable single-use capsule configuration, reusable membrane cartridges in sanitary housings or a combination of both.
No. Capsule filters are widely useful during development and pilot work, but they can also remain part of compatible single-use pharmaceutical and biopharmaceutical production processes. The correct format depends on filtration area, throughput, batch size, system architecture and validation requirements.
A cartridge system may be appropriate when greater filtration area, multiple filter elements, a reusable sanitary installation or integration into permanent process equipment is required. A format change should be driven by process requirements rather than by scale alone.
Where suitable configurations are available, maintaining comparable membrane chemistry and filtration characteristics across capsule and cartridge formats can help preserve relevant development data during scale-up. The exact production filter must still be evaluated and validated for its intended process.
Useful scale-up data includes representative product throughput per filtration area, flow rate, differential-pressure behaviour, process time, batch volume, product compatibility and an appropriate operating margin.
No. Reusable sanitary housings are one production architecture, but suitable validated single-use filtration systems can also be used in pharmaceutical and biotechnology manufacturing. The choice depends on the process and manufacturing strategy.
Where integrity testing is required, the strategy should be considered during development so the membrane, wetting procedure, test method, acceptance criteria and production equipment can remain aligned with the final validated process.
Depending on the membrane and application, methods can include Diffusion or Forward Flow, Bubble Point and Water Flow or Water Intrusion-type testing. The appropriate method and test limits must correspond to the exact filter configuration and validated process.
No. Pore rating alone does not establish sterilizing-grade validation. The exact filter configuration must have appropriate validation for the intended application and its specified operating and integrity-test limits must be followed.
Yes. A pharmaceutical process can use disposable bags, tubing and capsule filters in selected steps while using membrane cartridges and sanitary stainless-steel housings elsewhere. Hybrid systems are selected according to the requirements of each process stage.
Changes in membrane chemistry, filter configuration, operating conditions or integrity-testing methodology can alter process performance. Their impact therefore needs to be evaluated and, where applicable, supported by additional qualification, validation or documentation.
